Document is current
Any future updates will be listed below
-
Authors
Martinez Chanza, Nieves https://orcid.org/0000-0002-2340-7415
Soukane, Louisa
Barthelemy, Philippe
Carnot, Aurélien
Gil, Thierry
Casert, Vinciane
Vanhaudenarde, Vincent
Sautois, Brieuc
Staudacher, Lionel
Van den Brande, Jan
Culine, Stephane
Seront, Emmanuel
Gizzi, Marco
Albisinni, Simone
Tricard, Thibault
Fantoni, Jean Christophe
Paesmans, Marianne
Caparica, Rafael
Roumeguere, Thierry
Awada, Ahmad
-
Funding
Funding for this research was provided by:
This study is financially supported by Merck N.V.-S.A., Overijse, Belgium, an affiliate of Merck KGaA, Darmstadt, Germany, as part of an alliance between Merck KGaA and Pfizer.
- License Information
-
More Information
Article History
Received: 30 September 2020
Accepted: 10 November 2021
First Online: 2 December 2021
Declarations
:
: Not applicable. No data are presented in this article.
: This study has been approved by the Ethics Committee of the Jules Bordet Institut, Institut de Cancérologie Strasbourg Europe ICANS, Centre Oscar Lambret, Centre Hospitalier Universitaire de Ambrois Paré, Clinique Sainte-Elisabeth, University Hospital of Liege, Hopital Paris Saint Joseph, University Hospital Antwerp, Hopital Saint-Louis and Grand Hopital de Charleroi. Patients must provide written informed consent before enrollment. All the patients will be free to participate in this study and can decide to withdraw at any time. Any modifications of the protocol that may impact the conduct of the study, potentially benefit the patients or that may affect patient safety, including changes in study design, sample size and study procedures, will require a formal amendment to the protocol. Additionally, this would need to be submitted to the Hospital Ethics Committee and health authorities must be notified in accordance with local regulations.
: NMC reports support for research travel from Pfizer and Ipsen, and consulting fees for BMS and Bayer, none related to the present work. RC has received speaker honoraria from Boehringer-Ingelheim, AstraZeneca and Janssen; and travel grants from Pfizer and AstraZeneca, none related to the present work. MG reports support for research travel and consulting fees from Pfizer, none related to the present work. BS has served a consulting or advisory role for Clovis Oncology, Astellas, Janssen, and Sanofi and received financial support for travel and/or accommodation from Janssen, none related to the present work. AC reports support for research travel from Pfizer, Merck Serono, Ipsen, BMS and MSD Oncology, and speaker honoraria from Pfizer and Amgen, none related to the present work. The rest of the authors declare no conflict of interest.
